1. Holland, E. C. (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A. 97, 6242–6244.
2. Castro, M. G., Cowen, R., Williamson, I. K., David, A., Jimenez-Dalmaroni, M. J., Yuan, X., Bigliari, A., Williams, J. C., Hu, J., and Lowenstein, P. R. (2003) Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther. 98, 71–108.
3. Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M., Brandes, A. A., Cairncross, G., Lacombe, D., and Mirimanoff, R. O. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy(RT) for newly diagnosed glioblastoma multiforme (GBM) (2004). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J Clin Oncol (Meeting Abstracts). 22, 2.
4. Ehtesham, M., Black, K. L., and Yu, J. S. (2004) Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control
11, 192–207.
5. Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Finger, D. N., Lee, P. K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., Zhang, W., Prins, R. M., and Black, K. L. (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842–847.